Carmen Saiz Guisasola, Specialist Physician at HM Hospitales, shared on LinkedIn:
“Huge congratulations to all the EMBRACE collaborators for this outstanding achievement!
It was a true honour to witness the presentation of the EMBRACE-II results this morning at ESTRO2025.
EMBRACE-II: The new standard of care for locally advanced cervical cancer
A beautifully executed protocol combining:
- IGRT/IMRT (45 Gy) with tight margins and risk-adapted planning
- Lymph node SIB (57 Gy)
- MRI-guided adaptive brachytherapy (IC/IS)
- Multi-parametric planning balancing CTVHR D90 ≥90 Gy & OAR limits
- Cisplatin-based chemotherapy & timely delivery (42–45 days)
Results (3y):
- Local control: 93%
- Nodal control: 91%
- Distant control: 88%
- Overall survival: 87%
- Disease-specific survival: 89%
- Severe late toxicity (G3–5): only 8.9% (G4 <1%, G5 <0.2%)
Compared to EMBRACE-I:
- Disease progression ↓ 17%
- Death ↓ 25%
- G3–G5 morbidity ↓ 45%
A protocol that is valid, reproducible and predictive – truly practice-defining!
Also, kudos to the FAST-FORWARD team for showing that:
26 Gy in 5 fractions is safe and non-inferior to 40 Gy in 15 for adjuvant axillary RT:
- No extra arm/hand swelling
- No brachial plexopathy
- Low recurrence expected
Clinical excellence advancing patient care and quality of life.”
See more posts featuring ESTRO 2025.
